WO2008067061A3 - Compositions and methods for modulating angiogenesis - Google Patents

Compositions and methods for modulating angiogenesis Download PDF

Info

Publication number
WO2008067061A3
WO2008067061A3 PCT/US2007/081653 US2007081653W WO2008067061A3 WO 2008067061 A3 WO2008067061 A3 WO 2008067061A3 US 2007081653 W US2007081653 W US 2007081653W WO 2008067061 A3 WO2008067061 A3 WO 2008067061A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
modulating angiogenesis
angiogenesis
modulating
Prior art date
Application number
PCT/US2007/081653
Other languages
French (fr)
Other versions
WO2008067061A2 (en
Inventor
Huiyan Zeng
Harold F Dvorak
Original Assignee
Beth Israel Hospital
Huiyan Zeng
Harold F Dvorak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital, Huiyan Zeng, Harold F Dvorak filed Critical Beth Israel Hospital
Publication of WO2008067061A2 publication Critical patent/WO2008067061A2/en
Publication of WO2008067061A3 publication Critical patent/WO2008067061A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods and compositions for identifying therapeutic agents for the treatment of disorders associated with aberrant angiogenesis are provided.
PCT/US2007/081653 2006-10-19 2007-10-17 Compositions and methods for modulating angiogenesis WO2008067061A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85280806P 2006-10-19 2006-10-19
US60/852,808 2006-10-19

Publications (2)

Publication Number Publication Date
WO2008067061A2 WO2008067061A2 (en) 2008-06-05
WO2008067061A3 true WO2008067061A3 (en) 2009-01-15

Family

ID=39468576

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/081653 WO2008067061A2 (en) 2006-10-19 2007-10-17 Compositions and methods for modulating angiogenesis

Country Status (1)

Country Link
WO (1) WO2008067061A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018536384A (en) * 2015-09-10 2018-12-13 ラ ホヤ インスティチュート フォー アラジー アンド イムノロジー Methods and compositions for modulating monocyte populations and related uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203013A1 (en) * 2002-04-11 2005-09-15 Shay Soker Methods for inhibiting vascular permeability
KR20060038790A (en) * 2004-11-01 2006-05-04 이미옥 Novel angiogeneic agent comprising activator of nur77 gene

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203013A1 (en) * 2002-04-11 2005-09-15 Shay Soker Methods for inhibiting vascular permeability
KR20060038790A (en) * 2004-11-01 2006-05-04 이미옥 Novel angiogeneic agent comprising activator of nur77 gene

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM ET AL.: "Menin Represses JunD Transcriptional Activity in Protein Kinase C Theta-mediated Nur77 Expression", EXPERIMENTAL AND MOLECULAR MEDICINE, vol. 37, no. 5, October 2005 (2005-10-01), pages 466 - 475 *
ZENG H. ET AL.: "Orphan Nuclear Receptor TR3/Nur77 Regulates VEGF-A-induced Angiogenesis Through its Transcriptional Activity", JEM, vol. 203, no. 3, March 2006 (2006-03-01), pages 719 - 729 *

Also Published As

Publication number Publication date
WO2008067061A2 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
WO2007059108A3 (en) Substituted quinolones and methods of use
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
WO2010060937A3 (en) Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor
MX2009006536A (en) Organic compounds and their uses.
WO2007109120A3 (en) Imidazolothiazole compounds for the treatment of disease
IL233634A0 (en) Methods, compositions, and kits for the treatment of medical conditions
WO2008054676A3 (en) Medical devices and methods of using the same
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
HK1166983A1 (en) Solid forms comprising compounds for the treatment of diseases or disorders, compositions thereof, and use therewith
MY147247A (en) Organic compounds and their uses
WO2008067121A3 (en) Methods of treating cognitive impairment and dementia
IL193747A0 (en) New therapeutic combinations for the treatment of depression
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
IL201509A0 (en) sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS
ZA200901523B (en) Use of extracts for the treatment of viral disorders
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2007101161A8 (en) Methods and compositions for the treatment of gastrointestinal disorders
SI2024368T1 (en) 6,7,8,9-tetrahydro-5h-pyrimidoš4,5-dćazepin-4-ylć-amine derivatives as modulators of trpv1 for the treatment of pain
WO2008027600A3 (en) Imatinib compositions
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2007122382A3 (en) Lycopene for the treatment of metabolic dysfunction
WO2007121125A3 (en) Hcv inhibitors
WO2009009417A3 (en) Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
EP2217238A4 (en) Methods and compositions for the treatment of proteinuric diseases
WO2007109288A3 (en) Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07871178

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07871178

Country of ref document: EP

Kind code of ref document: A2